Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities despite facing significant customer revenue loss.

Opus Genetics, Inc. announced that three abstracts concerning its investigational gene therapy candidates will be presented at the ARVO 2025 Meeting in Salt Lake City, UT, from May 4-8, 2025. The ...

RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore visio ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

Oklahoma Genetics Inc. has announced a new wheat variety called Orange Blossom CL+, which has the official release to move forward with commercialization. Brett Carver, regents professor and wheat ...

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.F ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Fulgent Genetics, Inc. (NASDAQ:FLGT) stands against the other ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and str ...